Flaig Research Lab

The Flaig Lab is focused on developing better intravesical bladder cancer therapeutics. Intravesical BCG has been used regularly for localized bladder cancer since the 1970’s. Despite the longevity of use, clinically relevant adverse events and bladder cancer recurrences remain common after BCG therapy. The Flaig Lab has established several in vivo models of bladder cancer locally for the evaluation of novel therapies.

Lab Personnel

Thomas Flaig, MD

Principal Investigator

Alex Hughes, PhD

Assistant Professor, Research

Joseph Petraccione, BS

Sr. Research Services Professional

Selected Publications

Yang X, Kessler E, Su, L Thorburn A, Frankel AE, Li Y, La Rosa FG, Shen J, Li C, Varella-Garcia M, Glodé LM, Flaig TW. Diphtheria Toxin–Epidermal Growth Factor Fusion Protein DAB389EGF for the Treatment of Bladder Cancer. Clinical Cancer Research. 2013; 19(1): 148-57. PMID: 23172881.

Cho SK, Emoto K, Su LJ, Yang X, Flaig TW, Park W. Functionalized gold nanorods for thermal ablation treatment of bladder cancer. J Biomed Nanotechnol. 2014 Jul;10(7):1267-76. PMID: 24804547

Yang X, Su LJ, La Rosa FG, Smith EE, Schlaepfer IR, Cho SK, Kavanagh B, Park W, Flaig TW. The Antineoplastic Activity of Photothermal Ablative Therapy with Targeted Gold Nanorods in an Orthotopic Urinary Bladder Cancer Model. Bladder Cancer. 2017 Jul 27;3(3):201-210. doi: 10.3233/BLC-170096. PMID: 28824948

Yang X, Su LJ, La Rosa FG, Smith EE, Schlaepfer IR, Cho SK, Kavanagh B, Park W, Flaig TW. The Antineoplastic Activity of Photothermal Ablative Therapy with Targeted Gold Nanorods in an Orthotopic Urinary Bladder Cancer Model. Bladder Cancer. 2017 Jul 27;3(3):201-210. doi: 10.3233/BLC-170096. PMID: 28824948

CMS Login